SCHEMBL6929889

SCHEMBL6929889

CCN(CC)C(C)n1c(NC(=O)c2ccc(C)cc2)nc2ccc(OC)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 2/20 0.47
AHR P35869 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
KDM4E B2RXH2 3/20 0.46
TSHR P16473 2/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ADORA1 P30542 3/20 0.46
ADORA2B P29275 1/20 0.46
TP53 P04637 4/20 0.45
RORC P51449 1/20 0.43
RXFP1 Q9HBX9 2/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929891 0.80 ALDH1A1 (0.60) ADORA3IRAK4RAB9ANPC1SMN1; SMN2
Diethylamine SCHEMBL6929894 0.78 IRAK4 (0.53) ADORA3IRAK4RAB9ANPC1SMN1; SMN2
SCHEMBL6932644 0.75 KDM4E (0.58) ADORA3IRAK4RAB9ANPC1SMN1; SMN2
SCHEMBL6934460 0.74 S1PR1 (0.41) SMN1; SMN2MEN1KMT2AHPGDHTT
SCHEMBL17582863 0.70 MEN1 (0.46) RAB9ANPC1LMNAMEN1KMT2A
SCHEMBL17582867 0.70 MEN1 (0.46) RAB9ANPC1LMNAMEN1KMT2A
SCHEMBL3604861 0.67 IRAK4 (0.80) ADORA3IRAK4RAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL6930435 0.66 RAB9A (0.62) ADORA3IRAK4RAB9ANPC1SMN1; SMN2
SCHEMBL11705152 0.66 RAB9A (0.68) IRAK4RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL4913650 0.66 SCD (0.88) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660870-B1 Serotonergic compounds which possess agonist activity at 5-HT2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma ALCON, INC. (CH) 2003-12-09 US disclosed